What’s Next in Workup for Portal Vein Thrombosis?

DDW 2025. Colonoscopic delivery of fecal therapy prevented recurrent C. diff infection in 95% of participants for 8 weeks, with mild GI adverse events reported by <10%.

Recurrent C difficile requires pulse vancomycin therapy; fecal microbiota transplant shows promise.

Your daily dose of the clinical news you may have missed.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.